n-3 fatty acids and renal diseases.
There are numerous biologic rationales for the use of n-3 fatty acids in renal diseases, including a possible increase in the renal vasodilatory capacity by a rearrangement of renal prostanoid production, a reduction in the production of proinflammatory leukotrienes, a reduction in the transcapillary escape rate of albumin, and actions limiting cyclosporine-related nephrotoxicity. Studies of animal models of renal disease, mostly of immune-renal disease, support the idea of the possible usefulness of these compounds. The most promising areas of clinical investigation include the reduction of proteinuria in some chronic glomerular diseases, the treatment of immunoglobulin A nephropathy, and the prevention of cyclosporine-induced nephrotoxicity. However, the results of larger clinical studies, some of which are ongoing, are necessary to support the use of n-3 fatty acids in human renal diseases.
De Caterina
R
R
CNR Institute of Clinical Physiology, Pisa, Italy.
Endres
S
S
Kristensen
S D
SD
Schmidt
E B
EB
D000818:Animals; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000503:physiopathology
D015525:Fatty Acids, Omega-3